workingonhere98
Active member
the Canadian generic pathway creating a significant cost reduction is real and tracking ahead of the US timeline - the regulatory and patent environment there moves faster on generics, and the community pricing reports from Canada at the generic stage are consistently below /month. whether that pricing remains accessible for cross-border access depends on how the import regulatory situation evolves